This page shows the latest Raxone news and features for those working in and with pharma, biotech and healthcare.
If approved, the gene therapy would compete with Santhera's Raxone, which became the first approved treatment for LHON in Europe in 2015.
These include the use of CRISPR/Cas9, myostatin Inhibitior candidates from Pfizer and BMS, and Santhera which is developing Idebenone (Raxone).
European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone). ... It’s the second such knock-back for Raxone’s licence extension and shares in the Swiss firm
Hopes to broaden reach of its Duchenne muscular dystrophy study
FDA rejects accelerated marketing application for Raxone to await phase II trial results. ... Santhera is facing a considerable delay in the US before it can get approval for Duchenne muscular dystrophy (DMD) candidate Raxone.
There has been some good news for European DMD patients this week however after Santhera announced it had filed for approval of Raxone (idebenone) for the treatment of DMD.
More from news
Approximately 5 fully matching, plus 6 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...